Developing disease-modifying nitro fatty acid platform technology for patients with fibrosis and inflammation-associated orphan diseases.
- Year invested 2017
- Investment Stage Early
- Sectors
- Investment Status Historic
- Website complexarx.com/
- Company Status Private